The United Laboratories International Holdings Limited (ULIHF)
OTCMKTS · Delayed Price · Currency is USD
1.640
0.00 (0.00%)
Aug 7, 2025, 8:00 PM EDT
Paramount Global Revenue
In the year 2024, The United Laboratories International Holdings had annual revenue of 13.76B CNY with 0.14% growth. The United Laboratories International Holdings had revenue of 6.58B in the half year ending December 31, 2024, with 7.00% growth.
Revenue
13.76B CNY
Revenue Growth
+0.14%
P/S Ratio
2.05
Revenue / Employee
809.35K CNY
Employees
17,000
Market Cap
3.86B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13.76B | 19.06M | 0.14% |
| Dec 31, 2023 | 13.74B | 2.41B | 21.22% |
| Dec 31, 2022 | 11.33B | 1.63B | 16.81% |
| Dec 31, 2021 | 9.70B | 930.95M | 10.61% |
| Dec 31, 2020 | 8.77B | 379.89M | 4.53% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| Global Cord Blood | 196.10M |
The United Laboratories International Holdings News
- 5 months ago - Novo Nordisk Strikes $2B Deal for Obesity Drug - Investopedia